Clinical trials: C-difficile
Clostridium Difficile Infection
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group II.
- Trial name
- ECOSPORIII (NCT03183128)
- Testing
- SER-109
- Where
- 56 sites in United States, Canada
- Volunteers
- 182 people
- Sponsor
- Seres Therapeutics, Inc.
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.
- Trial name
- NCT04000555
- Testing
- Oral Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Clostridioides Difficile Infection
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Cohort 1: Subjects who had a Clostridioides difficile infection (CDI) recurrence in study SERES-012 within 8 weeks of receipt of study drug will be eligible.
- Trial name
- NCT03183141
- Testing
- SER-109
- Where
- 107 sites in United States, Canada
- Volunteers
- 263 people
- Sponsor
- Seres Therapeutics, Inc.
Clostridium Difficile Infection
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
Data on the seroprevalence of antibodies to Clostridioides difficile surface proteins and toxins are scarce. In 1983, Viscidi et al. showed that antibodies to C.
- Trial name
- PREVADIFF (NCT05192148)
- Testing
- Patients
- Where
- 5 sites in France
- Volunteers
- 840 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Clostridium Infections, Clostridioides Difficile
Bezlotoxumab Versus FMT for Multiple Recurrent CDI
The objective of this trial is to investigate whether a treatment strategy offering bezlotoxumab before FMT in patients suffering from multiple recurrent CDI results in equal efficacy compared with a treatment strategy with…
- Conditions
- Clostridium Infections, Clostridioides Difficile, Enterocolitis, Pseudomembranous
- Trial name
- BSTEP (NCT05077085)
- Testing
- Bezlotoxumab, Fecal Microbiota Transplantation (FMT), Vancomycin oral
- Where
- 4 sites in Netherlands
- Sponsor
- Leiden University Medical Center
Clostridium Difficile Infection
Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection
This is a medical research study designed to look at the safety and efficacy of 30-day course of fidaxomicin for treatment of recurrent CDI (Clostridium difficile Infection).
- Trial name
- NCT02395848
- Testing
- Fidaxomicin
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McMaster University
Clostridium Difficile Infection
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
The purpose of the study is to determine the safety and efficacy of Fecal Microbiota Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI) as compared to standard antibiotic therapy.
- Trial name
- NCT02255305
- Testing
- FMT, Antimicrobials
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Endeavor Health
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical…
- Trial name
- NCT04317963
- Testing
- Bezlotoxumab, Standard CDI treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Illinois at Chicago
Clostridium Difficile Infection
Clostridium Difficile Vaccine Efficacy Trial
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium…
- Trial name
- Clover (NCT03090191)
- Testing
- Clostridium difficile vaccine
- Where
- 426 sites in United States, Argentina and 21 more
- Volunteers
- 17,535 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diarrhea Caused by Drug, Clostridium Difficile Infections
Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients
Rationale: Postantibiotic diarrhoea in critically ill patients is common, often prolonged and currently there is no effective treatment of it.
- Trial name
- FEBATRICE (NCT05430269)
- Testing
- Faecal bacteriotherapy (FBT), standard-of-care protocolised treatment of postantibiotic diarhea
- Where
- 2 sites in Czechia
- Volunteers
- 36 people
- Sponsor
- Charles University, Czech Republic
Clostridium Difficile Infection
FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness, associated with significant morbidity and mortality and has a high burden on health-care system.
- Trial name
- NCT02570477
- Testing
- Fecal Microbiota Transplantation, Vancomycin
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Clostridium Difficile Infection
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of…
- Trial name
- NCT02830542
- Testing
- SER-262
- Where
- 22 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seres Therapeutics, Inc.
Clostridium Difficile Associated Disease
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine.
- Trial name
- NCT03579459
- Testing
- Clostridium difficile vaccine
- Where
- 24 sites in United States
- Volunteers
- 1,317 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridioides Difficile Infection
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C.
- Trial name
- NCT04675723
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Clostridium Difficile Infection (CDI)
Treatment of Mild-moderate Clostridium Difficile Infection (CDI)
Patients diagnosed to have mild-moderate CDI will be randomized to receive IM-01 egg-derived anti-C. difficile polyclonal antibodies in increasing dosages, twice daily, for a total of 10 - 14 days.
- Trial name
- IM-01 (NCT04121169)
- Testing
- IM-01
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- ImmuniMed Inc.
Clostridium Difficile
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection
Fecal microbiota transplantation (FMT) has been very effective for patients who suffer from mild C diff infection (CDI) which recurs but it is unclear how effective FMT alone is in treating severe and fulminant CDI.
- Trial name
- NCT03760484
- Testing
- Fidaxomicin 200 mg, fecal microbiota transplantation (FMT)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University of Alberta
Clostridium Difficile
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
A total of 440 patients meeting enrollment criteria with a primary episode of C. Difficile Infection (CDI) will be enrolled across 3 sites.
- Trial name
- PROCLAIM (NCT03617172)
- Testing
- Misoprostol 100Mcg Tab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt University Medical Center
Clostridioides Difficile Infection
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been diagnosed with C.
- Trial name
- NCT04679324
- Sponsor
- Mayo Clinic
Clostridium Difficile
Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic therapy, will eliminate the high…
- Trial name
- NCT03937999
- Testing
- Bezlotoxumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Clostridium Difficile Infection Recurrence
A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
This is a randomized, placebo-controlled, double-blind, multi-site study in which up to approximately 36 subjects with a recent C.
- Trial name
- NCT04891965
- Testing
- ART24
- Where
- 15 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Adiso Therapeutics